Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 3:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 66 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: sofosbuvir/velpatasvir Clear all
Active, not recruiting Phase 4 Interventional

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy

NCT05140941
View directory record Official record
Conditions
Hepatitis C, Chronic, Pregnancy; Infection
Interventions
Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet
Drug
Lead sponsor
Catherine Anne Chappell
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
6
States / cities
Cincinnati, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia

NCT02825212
View directory record Official record
Conditions
Hepatitis C, Cryoglobulinemia
Interventions
Harvoni, Epclusa
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Results available

deLIVER: Direct Acting Antiviral Effects on the Liver

NCT02938013
View directory record Official record
Conditions
HCV Coinfection, Liver Disease, HIV
Interventions
Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX], Sofosbuvir/Velpatasvir (SOF/VEL)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

Expanding the Pool in Orthotopic Heart Transplantation

NCT03222531
View directory record Official record
Conditions
Hepatitis C, Heart Transplant, Cardiac Transplant
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Mary E. Keebler, MD
Other
Eligibility
18 Years to 71 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 20, 2026, 3:15 PM EDT
Terminated No phase listed Observational Results available

A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection

NCT02292706
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Sofosbuvir, Ribavirin, LDV/SOF, SOF/VEL, SOF/VEL/VOX, Other SOF-Based Regimen, Ineligible parent treatment
Drug · Other
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
77
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 57 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 20, 2026, 3:15 PM EDT
Terminated Phase 4 Interventional Results available

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

NCT03207399
View directory record Official record
Conditions
Hepatitis C, Chronic, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 20, 2026, 3:15 PM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Hepatitis C Positive Donor Into Hepatitis C Negative Recipients

NCT03702218
View directory record Official record
Conditions
Hepatitis C
Interventions
Direct Acting Antivirals
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 20, 2026, 3:15 PM EDT
Terminated Phase 4 Interventional Results available

Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy

NCT05717400
View directory record Official record
Conditions
Liver Cancer
Interventions
Bevacizumab, Atezolizumab, Sofosbuvir, Velpatasvir, Voxilaprevir, Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 2 Interventional

A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients

NCT04075916
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Epclusa
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
11
States / cities
Birmingham, Alabama • Gainesville, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 20, 2026, 3:15 PM EDT
Not listed Phase 4 Interventional

Curing HCV in Incarcerated Patients

NCT03018353
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Patients receiving Sof/Vel (Epclusa) and Navigation services
Drug
Lead sponsor
San Francisco Department of Public Health
Government
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Not applicable Interventional Results available

HCV Seek, Test and Rapid Treatment for Young PWID

NCT03627546
View directory record Official record
Conditions
Hepatitis C, Drug Use
Interventions
Rapid Treatment strategy, Usual Care (facilitated referral)
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 29 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA Experience

NCT02745535
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Sofosbuvir/Velpatasvir/Voxilaprevir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 3 Interventional Results available

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

NCT02625909
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 2 Interventional Results available

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

NCT03819322
View directory record Official record
Conditions
Liver Transplant, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Fernanda P Silveira, MD, MS
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 20, 2026, 3:15 PM EDT
Active, not recruiting Phase 4 Interventional

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

NCT03520660
View directory record Official record
Conditions
Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
Interventions
Epclusa
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 120 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

NCT02607735
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL/VOX, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Results available

The Kentucky Viral Hepatitis Treatment Study

NCT03949764
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders, Injection Drug Use
Interventions
Sofosbuvir/velpatasvir (Epclusa®)
Drug
Lead sponsor
Jennifer Havens
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Hazard, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection

NCT02220998
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
50
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 20, 2026, 3:15 PM EDT
Withdrawn Phase 4 Interventional

HCV Post-Exposure Prophylaxis for Health Care Workers

NCT03313414
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir/Velpatasvir Treatment for 14 days
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Results available

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

NCT03823911
View directory record Official record
Conditions
Cardiovascular Diseases, Hepatitis C, Hiv
Interventions
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI
Drug · Procedure
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 22, 2023 · Synced Oct 20, 2026, 3:15 PM EDT
Not listed Not applicable Interventional

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

NCT03164902
View directory record Official record
Conditions
Hepatitis C, Chronic, Nonadherence, Patient
Interventions
Digital Medicine
Device
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of SOF/VEL/VOX FDC for 12 Weeks and SOF/VEL for 12 Weeks in DAA-Experienced Adults With Chronic HCV Infection Who Have Not Received an NS5A Inhibitor

NCT02639247
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
43
States / cities
Long Beach, California • Los Angeles, California • Palo Alto, California + 40 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 1 Interventional Results available

Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir

NCT04382404
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir-Velpatasvir Drug Combination
Drug
Lead sponsor
Catherine Anne Chappell
Other
Eligibility
18 Years to 39 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 1, 2025 · Synced Oct 20, 2026, 3:15 PM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

NCT03057847
View directory record Official record
Conditions
Hepatitis C, Chronic, Opioid-use Disorder
Interventions
Sofosbuvir/Velpatasvir
Drug
Lead sponsor
Elizabeth Krans, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 20, 2026, 3:15 PM EDT